Study of antibodies to PMP22, IL-6 and TNF-alpha concentrations in serum in a CMTX1 family.
To further understand X-linked dominant Charcot-Marie-Tooth disease (CMTX1), we followed a family of 22 members in China, including 8 patients, 2 asymptomatic carriers and 12 normal family members. Twenty-two family members as well as 60 normal controls unrelated to this family were screened for point mutation by denaturing high performance liquid chromatography (DHPLC). All patients and asymptomatic carriers from this family, but none of the normal population controls, showed a T-C transition at position 266 in codon 89 of exon 2 of connexin 32, resulting in a leucine to proline (L89P) exchange. To study whether the immune system is involved in the pathogenesis of CMTX1 patients and asymptomatic carriers, we measured serum concentrations of antibodies to peripheral nerve myelin protein 22 (PMP22), interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-alpha) by ELISA. Serological results were also compared with those from GBS patients (n=11) and with normal subjects (n=20). Our analysis showed anti-PMP22 sera reactivity in 50.0% of CMTX1 patients, 63.6% of GBS patients and 10% of normal controls. Our results also indicated that anti-PMP22 antibodies in the CMTX1 family varied with sex. Anti-PMP22 antibodies were found in all male patients but not in all females, which may be one of the reasons that male patients usually have more severe clinical symptoms than that of female patients. There was no statistical difference in serum concentrations of IL-6 and TNF-alpha between CMTX1 patients and normal subjects. In conclusion, we identified a L89P mutation for the first time in a CMTX1 family in China and an associated response to PMP22 in males.
Da
Yuwei
Y
Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing 100053, China.
Jia
Jianping
J
D000906:Antibodies / Q000097:blood*; D002607:Charcot-Marie-Tooth Disease / Q000097:blood* / Q000235:genetics; D002681:China; D041321:Chromosomes, Human, X; D017630:Connexins / Q000235:genetics; D004252:DNA Mutational Analysis; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005192:Family Health; D005260:Female; D006801:Humans; D015850:Interleukin-6 / Q000276:immunology*; D007930:Leucine / Q000235:genetics; D008297:Male; D009185:Myelin Proteins / Q000276:immunology*; D017354:Point Mutation; D011392:Proline / Q000235:genetics; D012737:Sex Factors; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*; D000097002:Gap Junction beta-1 Protein
D000906:Antibodies; D017630:Connexins; D015850:Interleukin-6; D007930:Leucine; D009185:Myelin Proteins; D011392:Proline; D014409:Tumor Necrosis Factor-alpha; D000097002:Gap Junction beta-1 Protein; C073687:PMP22 protein, human